Overdose deaths involving BUP did not proportionally increase with new flexibilities in prescribing

The proportion of opioid overdose deaths involving buprenorphine, a medication used to treat opioid use disorder, did not increase in the months after prescribing flexibilities were put in place during the COVID-19 pandemic, according to a new study. These data provide evidence that may help to inform buprenorphine prescribing policies. Published today in JAMA Network Open, this study was a collaborative effort between researchers at the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, and the Centers for Disease Control and Prevention (CDC).

For more information, visit: https://www.nih.gov/news-events/news-releases/overdose-deaths-involving-buprenorphine-did-not-proportionally-increase-new-flexibilities-prescribing